Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and CNS disorders for both hospital and home settings.
Read more
Years of combined rare disease experience
Patients safely treated using therapeutically relevant doses of ganaxolone
Treatment approved specifically for CDKL5 deficiency disorder
Press Release
10-Q